Myron E Schwartz
Overview
Explore the profile of Myron E Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
3800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujiwara N, Lopez C, Marsh T, Raman I, Marquez C, Paul S, et al.
Gastroenterology
. 2024 Nov;
168(3):556-567.e7.
PMID: 39521255
Background & Aims: Hepatocellular carcinoma (HCC) risk stratification is an urgent unmet need for cost-effective HCC screening and early detection in patients with cirrhosis to improve poor HCC prognosis. Methods:...
2.
Marsh T, Parikh N, Roberts L, Schwartz M, Nguyen M, Befeler A, et al.
Gastroenterology
. 2024 Sep;
168(2):316-326.e6.
PMID: 39293548
Background & Aims: Better surveillance tests for hepatocellular carcinoma (HCC) are needed. The GALAD score (gender, age, α-fetoprotein [AFP] L3, AFP, and des-γ carboxyprothrombin) has been shown to have excellent...
3.
Tabrizian P, Holzner M, Ajmera V, Kim A, Zhou K, Schnickel G, et al.
J Hepatol
. 2024 Sep;
82(3):512-522.
PMID: 39255928
Background & Aims: The use of immune checkpoint inhibitors (ICIs) in patients with advanced hepatocellular carcinoma (HCC) has become widespread with encouraging outcomes in the neoadjuvant setting. Safety and intention-to-treat...
4.
Dharmapuri S, Cabal R, Akturk G, Ioannou G, Ozbey S, Paulsen J, et al.
Ann Transl Med
. 2024 Aug;
12(4):78.
PMID: 39118963
Background: Neoadjuvant chemotherapy (NACT) is increasingly being used in the management of locally advanced biliary tract cancer (BTC). The evidence suggests a contributing role of tumor infiltrating immune cells in...
5.
Holzner M, Mazzaferro V, Droz Dit Busset M, Aldrighetti L, Ratti F, Hasegawa K, et al.
Ann Surg Oncol
. 2024 Feb;
31(7):4397-4404.
PMID: 38334851
Background: Recurrence of intrahepatic cholangiocarcinoma (ICC) after liver resection (LR) remains high, and optimal therapy for recurrent ICC is challenging. Herein, we assess the outcomes of patients undergoing repeat resection...
6.
Park J, Nguyen V, Tsai P, Toyoda H, Leong J, Guy J, et al.
Aliment Pharmacol Ther
. 2024 Jan;
59(6):742-751.
PMID: 38173278
Background: Racial and ethnic disparities exist for hepatitis C virus (HCV) treatment and hepatocellular carcinoma (HCC) survival. Aim: To evaluate the impact of HCV treatment on such disparities. Methods: In...
7.
Wang X, He Q, Zhou C, Xu Y, Liu D, Fujiwara N, et al.
Immunity
. 2022 Dec;
56(1):58-77.e11.
PMID: 36521495
Obesity-induced chronic liver inflammation is a hallmark of nonalcoholic steatohepatitis (NASH)-an aggressive form of nonalcoholic fatty liver disease. However, it remains unclear how such a low-grade, yet persistent, inflammation is...
8.
Haber P, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehi M, Miho M, et al.
Gastroenterology
. 2022 Sep;
164(1):72-88.e18.
PMID: 36108710
Background & Aims: Single-agent anti-PD1 checkpoint inhibitors convey outstanding clinical benefits in a small fraction (∼20%) of patients with advanced hepatocellular carcinoma (aHCC) but the molecular mechanisms determining response are...
9.
Tabrizian P, Holzner M, Mehta N, Halazun K, Agopian V, Yao F, et al.
JAMA Surg
. 2022 Jul;
157(9):779-788.
PMID: 35857294
Importance: National guidelines on transplant selection have adopted successful downstaging to within Milan criteria (MC) as a viable option for the treatment of hepatocellular carcinoma (HCC) before liver transplant (LT)....
10.
Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez C, Jajoriya A, et al.
Sci Transl Med
. 2022 Jun;
14(650):eabo4474.
PMID: 35731891
Prediction of hepatocellular carcinoma (HCC) risk is an urgent unmet need in patients with nonalcoholic fatty liver disease (NAFLD). In cohorts of 409 patients with NAFLD from multiple global regions,...